Improving Blood Pressure Control with Candesartan Nanosuspension
Author Information
Author(s): Chetan Detroja, Sandip Chavhan, Krutika Sawant
Primary Institution: The Maharaja Sayajirao University of Baroda
Hypothesis
Can nanosuspension formulation enhance the bioavailability and antihypertensive activity of Candesartan cilexetil?
Conclusion
The study found that the nanosuspension of Candesartan significantly improved its antihypertensive effects compared to the plain drug suspension.
Supporting Evidence
- The nanosuspension showed a 22.44 times increase in saturation solubility compared to bulk Candesartan.
- In vivo studies demonstrated a 26.75% decrease in systolic blood pressure with the nanosuspension compared to 16% with the plain drug.
- Dissolution studies indicated that 99.4% of the nanosuspension dissolved within 15 minutes.
Takeaway
This study shows that making a medicine into tiny particles can help it work better in lowering blood pressure.
Methodology
The study involved preparing a nanosuspension of Candesartan cilexetil using media milling and evaluating its effects on blood pressure in hypertensive rats.
Potential Biases
Potential bias in animal model selection and treatment administration.
Limitations
The study was limited to a short-term evaluation of stability and pharmacodynamic effects.
Participant Demographics
Female Wistar rats, approximately 200-250 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website